Series A

The composite industries have thrived towards sustainability by leveraging the materials strength vs weight to reduce emissions from trains, planes, boats and vehicles. But in the process they generated a large volume of landfill materials from their post industrial excess of technical fibers. in carbon fiber alone, the excess is estimated at 42 thousand metric tons per year. That is about 92.6 million lbs a year of lost resources and supplies at an estimated value > $1B per year.

Globally, more than one billion individuals suffer from neuropsychiatric and mental health disorders, leading to an increased demand for medical help. Approximately 77 million individuals in the U.S. are on antidepressants, anti-anxiety, antipsychotics, and mood stabilizers, and 30% to 60% are treatment-resistant to these drugs.

Petram's mission is to be the most energy efficient rock-breaking technology on Earth. It is our vison to reduce the world's carbon footprint by 1,000,000 tons per year.

Each year, over 51 million surgeries are performed in the United States, each requiring numerous instrument trays to ensure patient safety and surgical efficiency. However, the sterile processing industry is grappling with severe labor shortages, leading to critical errors that can compromise safety and cause significant financial strain. Mistakes in sterile processing contribute to an estimated $25 billion in operating room delays, $16 billion in reprocessing costs, and $3.3 billion in patient infections annually.

The Problem

Inhaled nitric oxide (iNO) is a critical therapeutic gas with vasodilatory, anti-inflammatory, and antimicrobial properties, used to treat life-threatening conditions like pulmonary hypertension.

Current delivery systems are complex, costly, and restricted to major medical centers. They rely on highly diluted NO in nitrogen, require specialized scrubbers for toxic NO₂, frequent consumable changes, and large, non-portable equipment—limiting broader adoption and increasing care complexity.

Venous thromboembolism (VTE)—including deep vein thrombosis (DVT) and pulmonary embolism (PE)—remains a leading cause of morbidity and mortality worldwide.

Current standards of care have significant limitations:

PolyPV develops lightweight, flexible organic solar modules that deliver reliable power in challenging environments where traditional rigid panels fall short.

The technology addresses a critical need for defense, disaster relief, and remote operators: dependable, portable energy without stable infrastructure. Conventional solar solutions are bulky, fragile, and hard to transport—forcing reliance on heavy batteries or vulnerable fuel supply chains that reduce mobility and increase risk.

Grid reliability and resiliency remain challenged because distributed energy resources (DER) and microgrids have yet to drive transformative change in electric power systems.

Nhu Energy addresses this gap with high-performing digital operating technology (OT) that enables clean, flexible, and resilient distributed power at scale.

Our interoperable Operating Technology as a Service (OTaaS®) solutions deliver proven value to mission-critical facilities, including:

Myosin Therapeutics is a clinical and R&D-stage biotech C-corp incorporated in Delaware and based in South Florida.

The company’s innovative science was developed collaboratively in the labs of Drs. Miller, Griffin, and Kamenecka at the Department of Molecular Medicine, Wertheim UF Scripps Institute for Biomedical Innovation & Technology—a University of Florida research institute dedicated to new treatments.

PHIOGEN is a pre-clinical-stage biotechnology company developing first-in-class immunizing therapeutics designed to both treat drug-resistant infections and induce durable immune protection against recurrence, with a focus on chronic conditions.